NO970372D0 - Aroyloksy- og aroyltiopropanolamin-derivater anvendelige som <beta>-3-adrenoreseptor-agonister og antagonister for <beta>-1-og-<beta>-2-adrenoreseptorer og farmasöytiske blandinger derav - Google Patents
Aroyloksy- og aroyltiopropanolamin-derivater anvendelige som <beta>-3-adrenoreseptor-agonister og antagonister for <beta>-1-og-<beta>-2-adrenoreseptorer og farmasöytiske blandinger deravInfo
- Publication number
- NO970372D0 NO970372D0 NO970372A NO970372A NO970372D0 NO 970372 D0 NO970372 D0 NO 970372D0 NO 970372 A NO970372 A NO 970372A NO 970372 A NO970372 A NO 970372A NO 970372 D0 NO970372 D0 NO 970372D0
- Authority
- NO
- Norway
- Prior art keywords
- beta
- aroylthiopropanolamine
- adrenoreceptors
- aroyloxy
- antagonists
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 125000005333 aroyloxy group Chemical group 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/32—Esters thereof
- C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/3211—Esters of acyclic saturated acids which can have further substituents on alkyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
- C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
- C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
- C07C217/34—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/303—Cycloaliphatic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/32—Esters thereof
- C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/3223—Esters of cycloaliphatic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9415304A GB9415304D0 (en) | 1994-07-29 | 1994-07-29 | Novel compounds |
GB9423179A GB9423179D0 (en) | 1994-11-17 | 1994-11-17 | Novel compounds |
GBGB9510485.7A GB9510485D0 (en) | 1995-05-24 | 1995-05-24 | Novel compounds |
PCT/EP1995/003037 WO1996004233A1 (en) | 1994-07-29 | 1995-07-27 | Aryloxy and arylthiopropanolamine derivatives useful as beta 3-adrenoreceptor agonists and antagonists of the beta 1 and beta 2-adrenoreceptors and pharmaceutical composition thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
NO970372D0 true NO970372D0 (no) | 1997-01-28 |
NO970372L NO970372L (no) | 1997-03-18 |
Family
ID=27267307
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO970372A NO970372L (no) | 1994-07-29 | 1997-01-28 | Aroyloksy- og aroyltiopropanolamin-derivater anvendelige som <beta>-3-adrenoreseptor-agonister og antagonister for <beta>-1-og-<beta>-2-adrenoreseptorer og farmasöytiske blandinger derav |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0772585A1 (no) |
JP (1) | JPH10503507A (no) |
CN (1) | CN1159797A (no) |
AU (1) | AU3254695A (no) |
BR (1) | BR9508991A (no) |
CA (1) | CA2196193A1 (no) |
CZ (1) | CZ25597A3 (no) |
HU (1) | HUT76800A (no) |
MX (1) | MX9700765A (no) |
NO (1) | NO970372L (no) |
PL (1) | PL318381A1 (no) |
WO (1) | WO1996004233A1 (no) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9605495D0 (en) * | 1996-03-15 | 1996-05-15 | Smithkline Beecham Plc | Novel compounds |
US5914339A (en) * | 1996-05-14 | 1999-06-22 | American Home Products Corporation | Substituted 1,3-benzodioxoles |
ATE215369T1 (de) | 1996-09-05 | 2002-04-15 | Lilly Co Eli | Carbazolanaloge als selektive beta3-adrenergische agonisten |
WO1998022480A1 (en) * | 1996-11-18 | 1998-05-28 | Smithkline Beecham Plc | Phosphorus containing aryloxy or arylthio propanolamine derivatives |
GB9703492D0 (en) * | 1997-02-20 | 1997-04-09 | Smithkline Beecham Plc | Novel compounds |
CO5011072A1 (es) * | 1997-12-05 | 2001-02-28 | Lilly Co Eli | Etanolaminas pirazinil substituidas como agfonistas de los receptores |
DE69928185T2 (de) * | 1998-01-30 | 2006-07-20 | Boulder Scientific Co., Mead | Synthese von n-silylierten verbindungen |
US6495546B1 (en) | 1998-04-06 | 2002-12-17 | Fujisawa Pharmaceutical Co., Ltd. | Propanolamine derivatives |
AUPP549998A0 (en) * | 1998-08-26 | 1998-09-17 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
US7098248B2 (en) | 2001-07-09 | 2006-08-29 | Research Development Foundation | Beta-adrenergic blockade reversal of catabolism after severe burn |
DE102008064003A1 (de) * | 2008-12-19 | 2010-06-24 | Clariant International Limited | Verfahren zur Herstellung von mono-funktionalisierten Dialkylphosphinsäuren, -estern und -salzen und ihre Verwendung |
CN107266341B (zh) * | 2017-06-23 | 2020-01-07 | 华东师范大学 | 芳氧基取代丙-2-醇胺的衍生物作为β3肾上腺素能受体拮抗剂、制备方法和用途 |
CN112442167A (zh) * | 2019-08-28 | 2021-03-05 | 广东广山新材料股份有限公司 | 一种反应型阻燃剂及其制备方法和应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1262729A (en) * | 1983-10-19 | 1989-11-07 | Leo Alig | Phenoxypropanolamines |
DE3866984D1 (en) * | 1987-07-21 | 1992-01-30 | Hoffmann La Roche | Phenoxypropanolamine. |
GB8801306D0 (en) * | 1988-01-21 | 1988-02-17 | Ici Plc | Chemical compounds |
GB9215844D0 (en) * | 1992-07-25 | 1992-09-09 | Smithkline Beecham Plc | Novel compounds |
-
1995
- 1995-07-27 PL PL95318381A patent/PL318381A1/xx unknown
- 1995-07-27 CA CA002196193A patent/CA2196193A1/en not_active Abandoned
- 1995-07-27 AU AU32546/95A patent/AU3254695A/en not_active Abandoned
- 1995-07-27 JP JP8506193A patent/JPH10503507A/ja active Pending
- 1995-07-27 MX MX9700765A patent/MX9700765A/es unknown
- 1995-07-27 CZ CZ97255A patent/CZ25597A3/cs unknown
- 1995-07-27 HU HU9700262A patent/HUT76800A/hu unknown
- 1995-07-27 EP EP95929029A patent/EP0772585A1/en not_active Withdrawn
- 1995-07-27 WO PCT/EP1995/003037 patent/WO1996004233A1/en not_active Application Discontinuation
- 1995-07-27 BR BR9508991A patent/BR9508991A/pt not_active Application Discontinuation
- 1995-07-27 CN CN95195371A patent/CN1159797A/zh active Pending
-
1997
- 1997-01-28 NO NO970372A patent/NO970372L/no unknown
Also Published As
Publication number | Publication date |
---|---|
MX9700765A (es) | 1997-05-31 |
HUT76800A (en) | 1997-11-28 |
WO1996004233A1 (en) | 1996-02-15 |
CN1159797A (zh) | 1997-09-17 |
AU3254695A (en) | 1996-03-04 |
JPH10503507A (ja) | 1998-03-31 |
CZ25597A3 (cs) | 1998-02-18 |
NO970372L (no) | 1997-03-18 |
CA2196193A1 (en) | 1996-02-15 |
EP0772585A1 (en) | 1997-05-14 |
BR9508991A (pt) | 1997-10-21 |
PL318381A1 (en) | 1997-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO961432D0 (no) | Benzofiofener og beslektede forbindelser som östrogen-agonister | |
FI970310A0 (fi) | 4-indolijohdannaiset serotoniinin vaikuttaja- ja vastavaikuttaja-aineina | |
FI964576A (fi) | Uusia agonistiyhdisteitä | |
DK0832061T3 (da) | Benzamidderivater og anvendelse deraf som vasopressin-antagonister | |
DK1375503T3 (da) | Dioxinoderivater og deres anvendelse som dopaminagonister | |
NO990405D0 (no) | Substituerte N-(indol-2-karbonyl)-glycinamider og derivater som antidiabetiske midler | |
NO962322D0 (no) | Substituerte N-(indol-2-karbonyl)--alanimamider og derivater som antidiabetiske midler | |
FI944805A (fi) | Indolijohdannaisia 5-HT1-kaltaisina agonisteina | |
NO961887L (no) | -adrenergiske agonister | |
DE69736457D1 (de) | Interatomares messverfahren | |
NO307092B1 (no) | Sordaridin-derivater, anvendelse derav og farmasoeytisk blanding | |
FI961628A0 (fi) | Indolijohdannaisia NMDA-antagonisteina | |
NO970372D0 (no) | Aroyloksy- og aroyltiopropanolamin-derivater anvendelige som <beta>-3-adrenoreseptor-agonister og antagonister for <beta>-1-og-<beta>-2-adrenoreseptorer og farmasöytiske blandinger derav | |
BR9707812A (pt) | Composto composto farmacêutica e uso do composto | |
DE69402126D1 (de) | Anthracenderivate | |
FI962969A0 (fi) | Indolijohdannaisia 5-HT1:n agonisteina | |
DE69506826D1 (de) | 5-HT4 Rezeptoragonisten | |
PT755386E (pt) | Derivado de benzamida composicoes contendo o referido derivado e sua utilizacao | |
FR2727177B1 (fr) | Joint homocinetique fixe | |
NO963331D0 (no) | 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister | |
IT1277073B1 (it) | Derivati antraciclinici | |
DE59406275D1 (de) | Ausrichtadapter | |
NO996390L (no) | Cis-substituerte fluormetylpyrrolidin-derivater | |
NO995653L (no) | Cis-substituerte aminocykloalkyl-pyrrolidin-derivater | |
DK0944601T3 (da) | Heterocykliske quanidinylaminoforbindelser som alfa-2-adrenoceptoragonister |